menu
    • menu
    [{"orgOrder":0,"company":"Kalaris Therapeutics","sponsor":"AlloVir","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2024","type":"Merger","leadProduct":"TH103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Kalaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kalaris Therapeutics \/ Kalaris Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Kalaris Therapeutics \/ Kalaris Therapeutics"},{"orgOrder":0,"company":"Kalaris Therapeutics","sponsor":"AlloVir","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Protein","year":"2025","type":"Merger","leadProduct":"TH103","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Kalaris Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Kalaris Therapeutics \/ Kalaris Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Kalaris Therapeutics \/ Kalaris Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Kalaris Therapeutics

    Menu

    Kalaris Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kalaris Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Kalaris Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TH103

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Recipient : AlloVir

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Kalaris Announces Closing of Merger with AlloVir

                            Details : The combined company will focus on the development of TH103, a fully humanized, recombinant fusion protein, for patients with neovascular age-related macular degeneration.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            March 18, 2025

                            Lead Product(s) : TH103

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Recipient : AlloVir

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kalaris Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Kalaris Therapeutics

                            U.S.A arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TH103

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I

                            Recipient : AlloVir

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            AlloVir & Kalaris Merge, Focus on Retinal Disease Therapies

                            Details : The combined company will focus on the development of TH103, a fully humanized, recombinant fusion protein, for patients with neovascular age-related macular degeneration.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            November 08, 2024

                            Lead Product(s) : TH103

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I

                            Recipient : AlloVir

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth